BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 19, 2005
View Archived Issues
Fibrillex Misses; Neurochem Stock Drops By 28 Percent
While Fibrillex demonstrated a positive trend in AA amyloidosis patients, a Phase II/III trial missed its primary endpoint, causing Neurochem Inc.'s stock plunge of 28.5 percent. (BioWorld Today)
Read More
CV Therapeutics Reports Good Ranexa Data From Phase III
Read More
Nuvelo Begins Phase III Trial Of Alfimeprase In 'Leg Attack'
Read More
Onyx, Bayer Offer Sorafenib To All Pivotal Trial Patients
Read More
AACR News
Read More
Other News To Note
Read More